No Data
Aurisco Pharmaceutical (605116.SH): actively exploring application scenarios related to research, production, sales and other business areas that DeepSeek can access.
On March 13, Gelonghui reported that Aurisco Pharmaceutical (605116.SH) stated on the investor interaction platform that the company is actively exploring the application scenarios in the business fields related to R&D, production, and sales that can be connected to DeepSeek, aiming to further reduce costs and improve efficiency, thereby enhancing the company's competitiveness.
Aurisco Pharmaceutical (605116.SH): Share buyback has not yet been implemented.
Gelonghui February 7 report丨Aurisco Pharmaceutical (605116.SH) announced that as of January 31, 2025, the company has not yet implemented a share repurchase.
Aurisco Pharmaceutical Chairman Proposes Share Repurchase Plan
Aurisco Pharmaceutical (605116.SH): Plans to spend 60 million yuan to 0.12 billion yuan to repurchase shares.
Gelonghui January 21丨Aurisco Pharmaceutical (605116.SH) announced that the company plans to buy back shares for the conversion of the company's Convertible Bonds. The amount for the share buyback will not be less than 60 million RMB (inclusive) and will not exceed 120 million RMB (inclusive). The maximum price for this share buyback will not exceed 25.00 RMB per share.
Will Weakness in Aurisco Pharmaceutical Co.,Ltd.'s (SHSE:605116) Stock Prove Temporary Given Strong Fundamentals?
Aurisco Pharmaceutical (605116.SH): Currently, the company has no pharmaceutical products participating in the national centralized procurement.
On December 20, Gelonghui reported that Aurisco Pharmaceutical (605116.SH) stated on the investor interaction platform that the company currently has no pharmaceutical products participating in the national centralized procurement.
Aurisco Pharmaceutical Co.,Ltd. (SHSE:605116) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
